The FDA called it “a historic day” as insulin and certain other biologic drugs transitioned to a different regulatory pathway. The 10-year transition built into the Biologics Price Competition and ...
Medicare beneficiaries will pay no more than $35 a month for insulin in 2023, while ongoing work will be needed to ensure that everyone in the United States with diabetes who needs insulin can afford ...
The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study. Blocking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback